NCT04951856 - Evolocumab or Normal Strategies to Reach LDL Objectives in Acute Myocardial Infarction Upbound to PCI | Biotech Hunter

Enrollment

2,166

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

September 29, 2025

Study Completion Date

September 29, 2027

Conditions

STEMI - ST Elevation Myocardial InfarctionNSTEMI - Non-ST Segment Elevation MI

Interventions

DRUG

Evolocumab 140 MG/ML

Evolocumab (Repatha®) 140 mg every two weeks: first subcutaneous injection at the time of randomization, before PCI, followings during 12 months.

DRUG

Standard of care (SOC)

management as recommended in ESC/EAS 2019 guidelines, within reimbursement criteria

Trial Locations (1)

RECRUITING

ACTION Group, Institut de Cardiologie, Centre Hospitalier Universitaire Pitié Salpêtrière (APHP), UPMC, Paris